Answer
It is licensed as first-line hormone treatment for hormone-dependent metastatic breast cancer in postmenopausal patients. It is not recommended for oestrogen-receptor-negative tumours.
Sources for this answer
- Fareston 60mg Tabletsemc · SmPC Current selected SmPC · Version 12